MediVector, Inc. develops innovative therapeutic agents that address unmet medical needs and improve public health.
MediVector has consistently proven that it can significantly reduce the developmental time and cost of bringing a new molecular entity to market. The company works closely with large pharmaceutical, biotechnology, private equity, and venture companies to manage a drug through its entire clinical development program – from early to mid-stage clinical trials through FDA approval.
MediVector’s success is a result of its team’s clinical development, regulatory and science expertise complemented by proprietary processes and software based decision support systems and data management tools. The company’s management team has a track record of successfully transforming innovative therapeutics with highly challenging clinical and regulatory hurdles into blockbuster drugs that address unmet medical needs and improve public health.
Where science and finance meet.
If you are not creative, effective, and entrepreneurial in the drug development process, there is a danger of spending millions of dollars—and coming up with nothing.